• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis

by MM360 Staff | Oct 7, 2025 | Publications

Front Oncol. 2025 Sep 19;15:1545096. doi: 10.3389/fonc.2025.1545096. eCollection 2025. ABSTRACT BACKGROUND: Prognostic nutritional index (PNI) has been extensively investigated for its effect on forecasting multiple myeloma (MM) survival; however, the conclusions are...

The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review

by MM360 Staff | Sep 30, 2025 | Publications

Leuk Lymphoma. 2025 Sep 29:1-10. doi: 10.1080/10428194.2025.2560085. Online ahead of print. ABSTRACT Whilst T-cell directed therapies have revolutionized the therapeutic landscape in triple-class refractory multiple myeloma, ongoing long-term safety concerns remain,...

Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis

by MM360 Staff | Sep 26, 2025 | Publications

Ann Med. 2025 Dec;57(1):2560679. doi: 10.1080/07853890.2025.2560679. Epub 2025 Sep 24. ABSTRACT OBJECTIVE: Smoldering multiple myeloma (SMM) is a slowly progressive, asymptomatic plasma cell disorder. This meta-analysis evaluated the efficacy and safety of novel...

Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials

by MM360 Staff | Sep 14, 2025 | Publications

Cancers (Basel). 2025 Aug 22;17(17):2727. doi: 10.3390/cancers17172727. ABSTRACT Background: Multiple myeloma (MM) is an incurable plasma cell dyscrasia with particularly adverse prognosis in relapsed, multi-drug refractory settings. The management of those patients...

A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients

by MM360 Staff | Sep 3, 2025 | Publications

ESMO Open. 2025 Aug;10(8):105514. doi: 10.1016/j.esmoop.2025.105514. Epub 2025 Jul 15. ABSTRACT BACKGROUND: The treatment landscape for relapsed/refractory multiple myeloma (RRMM) is rapidly evolving, particularly for patients exposed or refractory to lenalidomide....

Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis

by MM360 Staff | Aug 19, 2025 | Publications

Haematologica. 2025 Aug 14. doi: 10.3324/haematol.2025.288174. Online ahead of print. ABSTRACT Not available. PMID:40820831 | DOI:10.3324/haematol.2025.288174
« Older Entries

Recent Content

  • Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma
  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT